CMS “Clamming Up” On Giving Medicaid Rx Rebate Advice, Attorneys Say
The Centers for Medicare & Medicaid Services is cutting off an important source of information on the Medicaid rebate statute in response to the Department of Justice's recent enforcement of best price reporting, attorneys told the American Conference Institute's forum on prescription drug pricing Oct. 20 in New York City
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth